This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, T.-Y. Articles by Robertson, K. D. Search for Related Content PubMed PubMed Citation Articles by Kim, T.-Y. Articles by Robertson, K. D.

Epigenomic Profiling Reveals Novel and Frequent Targets of Aberrant DNA Methylation-Mediated Silencing in Malignant Glioma

¹ Department of Biochemistry and Molecular Biology and University of Florida Shands Cancer Center Program in Cancer Genetics, Epigenetics, and Tumor Virology, University of Florida College of Medicine, Gainesville, Florida; ² Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine; and ³ Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Requests for reprints: Keith D. Robertson, Department of Biochemistry and Molecular Biology, University of Florida College of Medicine, Box 100245, 1600 Southwest Archer Road, Gainesville, FL 32610. Phone: 352-392-1810; Fax: 352-392-2953; E-mail: keithr{at}ufl.edu.

Malignant glioma is the most common central nervous system tumor of adults and is associated with a significant degree of morbidity and mortality. Gliomas are highly invasive and respond poorly to conventional treatments. Gliomas, like other tumor types, arise from a complex and poorly understood sequence of genetic and epigenetic alterations. Epigenetic alterations leading to gene silencing, in the form of aberrant CpG island promoter hypermethylation and histone deacetylation, have not been thoroughly investigated in brain tumors, and elucidating such changes is likely to enhance our understanding of their etiology and provide new treatment options. We used a combined approach of pharmacologic inhibition of DNA methylation and histone deacetylation, coupled with expression microarrays, to identify novel targets of epigenetic silencing in glioma cell lines. From this analysis, we identified >160 genes up-regulated by 5-aza-2'-deoxycytidine and trichostatin A treatment. Further characterization of 10 of these genes, including the putative metastasis suppressor CST6, the apoptosis-inducer BIK, and TSPYL5, whose function is unknown, revealed that they are frequent targets of epigenetic silencing in glioma cell lines and primary tumors and suppress glioma cell growth in culture. Furthermore, we show that other members of the TSPYL gene family are epigenetically silenced in gliomas and dissect the contribution of individual DNA methyltransferases to the aberrant promoter hypermethylation events. These studies, therefore, lay the foundation for a comprehensive understanding of the full extent of epigenetic changes in gliomas and how they may be exploited for therapeutic purposes. (Cancer Res 2006; 66(15): 7490-501)

This article has been cited by other articles:

				J. M. Friedman, G. Liang, C.-C. Liu, E. M. Wolff, Y. C. Tsai, W. Ye, X. Zhou, and P. A. Jones The Putative Tumor Suppressor microRNA-101 Modulates the Cancer Epigenome by Repressing the Polycomb Group Protein EZH2 Cancer Res., March 15, 2009; 69(6): 2623 - 2629. [Abstract] [Full Text] [PDF]

				J. M. McGough, D. Yang, S. Huang, D. Georgi, S. M. Hewitt, C. Rocken, M. Tanzer, M. P.A. Ebert, and K. Liu DNA Methylation Represses IFN-{gamma}-Induced and Signal Transducer and Activator of Transcription 1-Mediated IFN Regulatory Factor 8 Activation in Colon Carcinoma Cells Mol. Cancer Res., December 1, 2008; 6(12): 1841 - 1851. [Abstract] [Full Text] [PDF]

				J. M. Yi, H.-C. Tsai, S. C. Glockner, S. Lin, J. E. Ohm, H. Easwaran, C. D. James, J. F. Costello, G. Riggins, C. G. Eberhart, et al. Abnormal DNA Methylation of CD133 in Colorectal and Glioblastoma Tumors Cancer Res., October 1, 2008; 68(19): 8094 - 8103. [Abstract] [Full Text] [PDF]

				L. E. Kandalaft, E. Zudaire, S. Portal-Nunez, F. Cuttitta, and S. B. Jakowlew Differentially expressed nucleolar transforming growth factor-{beta}1 target (DENTT) exhibits an inhibitory role on tumorigenesis Carcinogenesis, June 1, 2008; 29(6): 1282 - 1289. [Abstract] [Full Text] [PDF]

				L. Bethke, E. Webb, A. Murray, M. Schoemaker, M. Feychting, S. Lonn, A. Ahlbom, B. Malmer, R. Henriksson, A. Auvinen, et al. Functional Polymorphisms in Folate Metabolism Genes Influence the Risk of Meningioma and Glioma Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1195 - 1202. [Abstract] [Full Text] [PDF]

				B. Jin, Q. Tao, J. Peng, H. M. Soo, W. Wu, J. Ying, C. R. Fields, A. L. Delmas, X. Liu, J. Qiu, et al. DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function Hum. Mol. Genet., March 1, 2008; 17(5): 690 - 709. [Abstract] [Full Text] [PDF]

				J. E. Dominy Jr., J. Hwang, and M. H. Stipanuk Overexpression of cysteine dioxygenase reduces intracellular cysteine and glutathione pools in HepG2/C3A cells Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E62 - E69. [Abstract] [Full Text] [PDF]